Our top pick for
InVivo Therapeutics Holdings Corp is a biotechnology business based in the US. InVivo Therapeutics shares (NVIV) are listed on the NASDAQ and all prices are listed in US Dollars. InVivo Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$26.7 million.
|52-week range||USD$0.5 - USD$7.85|
|50-day moving average||USD$1.2794|
|200-day moving average||USD$1.0825|
|Wall St. target price||USD$37.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.296|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-55.67%|
|Return on equity TTM||-130.92%|
|Market capitalisation||USD$26.7 million|
TTM: trailing 12 months
There are currently 3.9 million InVivo Therapeutics shares held short by investors – that's known as InVivo Therapeutics's "short interest". This figure is 149.6% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting InVivo Therapeutics shares can be evaluated.
InVivo Therapeutics's "short interest ratio" (SIR) is the quantity of InVivo Therapeutics shares currently shorted divided by the average quantity of InVivo Therapeutics shares traded daily (recently around 8.2 million). InVivo Therapeutics's SIR currently stands at 0.47. In other words for every 100,000 InVivo Therapeutics shares traded daily on the market, roughly 470 shares are currently held short.
However InVivo Therapeutics's short interest can also be evaluated against the total number of InVivo Therapeutics shares, or, against the total number of tradable InVivo Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InVivo Therapeutics's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 InVivo Therapeutics shares in existence, roughly 180 shares are currently held short) or 0.1849% of the tradable shares (for every 100,000 tradable InVivo Therapeutics shares, roughly 185 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InVivo Therapeutics.
Find out more about how you can short InVivo Therapeutics stock.
We're not expecting InVivo Therapeutics to pay a dividend over the next 12 months.
InVivo Therapeutics's shares were split on a 1:30 basis on 12 February 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your InVivo Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for InVivo Therapeutics shares which in turn could have impacted InVivo Therapeutics's share price.
Over the last 12 months, InVivo Therapeutics's shares have ranged in value from as little as $0.5 up to $7.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InVivo Therapeutics's is 1.7044. This would suggest that InVivo Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.